Absci Corporation
ABSI•NASDAQ•Healthcare•Biotechnology

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOSean McClain
Founded2011
IPO DateJuly 22, 2021
Employees157
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.absci.com
Phone360 949 1041
Address
18105 SE Mill Plain Boulevard Vancouver, Washington 98683 United States

Corporate Identifiers

CIK0001672688
CUSIP00091E109
ISINUS00091E1091
EIN85-3383487
SIC8731

Leadership Team & Key Executives

Sean McClain
Founder, Chief Executive Officer, President and Director
Dr. Zachariah Jonasson Ph.D.
Chief Business Officer and Chief Financial Officer
Dr. Andreas Busch Ph.D.
Chief Innovation Officer and Member of Scientific Advisory Board
Todd Bedrick CPA
Senior Vice President and Chief Accounting Officer
Alexander Khan CPA
Vice President of Finance and Head of Investor Relations
Shelby Walker J.D.
Chief Legal Officer
Karin Wierinck
Chief People Officer
Melissa Patterson Ph.D.
Chief of Staff
Wen Sha
Chief of Staff
Dr. Christine Lemke D.V.M., M.B.A., Ph.D.
Senior Vice President of Portfolio and Growth Strategy